CIK 0001774857 · <br>Emerging growth company
Aardvark Therapeutics, Inc.
Sign in to watch- Ticker
- AARD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821606367
- Phone
- (858) 225-7696
- Business address
- 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA, 92122
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $394,957
- in 1 filing, $395K under 10b5-1 plans
Net −$394,957. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-28 | Lee Tien-Li Chief Executive Officer | Option exercise | +17,209 | $4.24 | $73K | 1,513,384 |
| 2025-08-28 | Lee Tien-Li Chief Executive Officer | Option exercise · Stock option (right to buy) | −17,209 | 41,795 | ||
| 2025-06-11 | Lee Tien-Li Chief Executive Officer | Grant or award · Stock option (right to buy) | +549,534 | 549,534 | ||
| 2025-06-11 | Chi Jeffrey Director | Grant or award · Stock Option (right to buy) | +61,017 | 61,017 | ||
| 2025-06-11 | Jaiman Manasi Chief Medical Officer | Grant or award · Stock Option (right to buy) | +126,999 | 126,999 | ||
| 2025-06-11 | Sun Nelson Chief Financial Officer | Grant or award · Stock Option (right to buy) | +209,826 | 209,826 | ||
| 2025-06-11 | Baynes Roy D. Director | Grant or award · Stock Option (right to buy) | +30,508 | 30,508 | ||
| 2025-06-11 | Tong Victor Edward Jr Director | Grant or award · Stock Option (right to buy) | +61,017 | 61,017 | ||
| 2025-06-11 | Jones Bryan Chief Operating Officer | Grant or award · Stock Option (right to buy) | +122,033 | 122,033 | ||
| 2025-06-11 | Graf Susan E Director | Grant or award · Stock Option (right to buy) | +30,508 | 30,508 | ||
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion | +2,333,887 | 2,333,887 | ||
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion | +333,412 | 333,412 | ||
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Purchase | +625,000 | $16.00 | $10.0M | 2,958,887 |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Purchase | +625,000 | $16.00 | $10.0M | 958,412 |
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −19,777,363 | 0 | ||
| 2025-02-14 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion · Series C Convertible Preferred Stock | −2,825,337 | 0 | ||
| 2025-02-14 | Chi Jeffrey Director | Conversion | +133,364 | 133,364 | ||
| 2025-02-14 | Chi Jeffrey Director | Conversion · Series C Convertible Preferred Stock | −1,130,135 | 0 | ||
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd 10% owner | Conversion | +1,637,411 | 1,637,411 | ||
| 2025-02-14 | Vickers Venture Fund VI Pte Ltd 10% owner | Conversion | +413,491 | 2,050,902 |
Page 3 of 4 · 71 trades